Reviewed 10 November 2026 for medical education. This material is not a prescribing protocol; apply local clinical guidance and individual assessment.
Scope
This companion to the postpartum-haemorrhage uterotonic review focuses on agents that initiate or strengthen contractions before delivery. Labour induction and augmentation have distinct indications and must not be confused with routine prophylactic PPH therapy [1–3].
Oxytocin and receptor physiology
Oxytocin is a cyclic nonapeptide, not a ‘nonapeptide pentapeptide.’ It activates Gq-coupled oxytocin receptors, stimulating phospholipase C, IP3-mediated calcium release and uterine contraction. Oxytocin-receptor expression and uterine responsiveness change across gestation. Intravenous oxytocin has a short circulating half-life, allowing titration but requiring continuous assessment of uterine contractions and fetal heart rate where indicated [1].
Agents used to induce labour
- Oxytocin infusion: used for induction or augmentation under locally approved protocols, generally after assessment of cervical favorability, presentation and contraindications.
- Dinoprostone (PGE2): vaginal preparations promote cervical ripening and uterine contractions.
- Misoprostol (PGE1 analogue): may be used for cervical ripening/induction under gestational and institutional protocols; its safety and appropriate route/dose differ markedly across indications.
- Mechanical methods: balloon catheters are nonpharmacological cervical-ripening options.
Carbetocin is primarily used for PPH prevention, not routine induction. Desmopressin is not an oxytocic, and atosiban is a tocolytic antagonist [1–3].
Safety of induction
Excessive uterine activity (tachysystole) can impair fetal oxygenation. Continuous intrapartum monitoring, assessment for hyperstimulation and adjustment/cessation of induction agents are important. Misoprostol and other prostaglandins require specific caution or avoidance with prior cesarean scar or major uterine surgery because of rupture risk. IV oxytocin can cause hypotension if given rapidly and water intoxication/hyponatremia with large prolonged doses and inappropriate fluids [1,2].
Clinical assessment
Assess maternal and fetal indications, gestational age, membrane status, prior uterine surgery and cervical condition before induction. Contraindications to vaginal birth (for example placenta previa or transverse lie) generally preclude routine induction. Use only local institution-specific dosing and safety protocols; drug use in the first/second trimester and pregnancy termination follows different specialty guidance [1,2].
Distinct from PPH treatment
After delivery, oxytocin 10 IU IM/IV is recommended by WHO for prevention of PPH, but this dose must not be copied into a labour-induction infusion protocol. Recognize the different therapeutic goals, timing and monitoring requirements [3].
References
- Brunton LL, Knollmann BC, editors. Goodman & Gilman’s The Pharmacological Basis of Therapeutics. 14th ed. McGraw Hill; 2023.
- National Institute for Health and Care Excellence. Inducing labour. NICE guideline NG207. Available from: https://www.nice.org.uk/guidance/ng207/chapter/Recommendations
- World Health Organization. Consolidated guidelines for the prevention, diagnosis and treatment of postpartum haemorrhage. 2025. Available from: https://www.ncbi.nlm.nih.gov/books/NBK619233/table/ch3.tab7/
Medical & AI Disclaimer
The information provided on Sumathi Publications is for general educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional regarding any medical condition or treatment decision.
We strive to keep our content accurate and up to date; however, some content may be created or assisted using artificial intelligence (AI) and may contain errors or omissions. All information should be independently verified before use. Reliance on any content provided by Pharmacology Mentor is at your own risk.